HeartBeam, Inc.
Close on Oct 19, 2026
- Market cap
- $1.07M
- P/E (TTM)
- –
- Dividend yield
- –
About HeartBeam
Surgical & Medical Instruments & Apparatus, SIC 3841
HeartBeam is a medical technology company that develops ambulatory cardiac monitoring solutions designed for use outside clinical environments. The company's primary offering is the HeartBeam System, a cable-free cardiac monitoring platform comprising a credit-card-sized three-dimensional electrocardiogram (ECG) recording device, a patient mobile application, cloud-based algorithms, and a web-based physician portal. The system records electrical signals from the heart across three dimensions to synthesize twelve-lead ECG readings for remote arrhythmia assessment, supported by continuous access to on-demand cardiologists. Target customers include concierge physicians, preventive cardiology practices, and hospital cardiology departments.
The company operates primarily within the United States, targeting initial commercialization through select cardiology practices and direct sales channels, while exploring potential international expansion opportunities. HeartBeam employed 16 personnel as of late 2025, expanding to 17 staff members in early 2026. The provided text does not disclose the company's specific headquarters location.
Summary of the business section of HeartBeam's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HeartBeam, Inc.
- Headquarters
- Santa Clara, CA
- Address
- 2118 Walsh Ave., Suite 210 95050
- Phone
- (408) 899-4443
- Employees
- 16, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- BEATW
- Other tickers
- BEAT
- Exchange
- Nasdaq
- Shares outstanding
- 56M, Aug 11, 2026
- Public float
- $36.37M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1779372
- CUSIP
- 42238H116
- ISIN
- US42238H1169
- EIN
- 47-4881450
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Branislav Vajdic | President, Director | 3,970,784 |
| Tim Cruickshank | CFO | 239,990 |
| Kenneth Harry Persen | Chief Technology Officer | 448,290 |
| Robert Paul ENO | President | 36,742 |
| Richard Ferrari | Director | 352,289 |
| Michael R. Jaff | Director | 127,059 |
| Marga Ortigas-Wedekind | Director | 154,117 |
| Mark E. Strome | Director | 3,707,146 |
| Willem Elfrink | Director | 645,492 |
| Kenneth Warwick Nelson III | Director | 144,388 |
| Urioste George de | Director | 0 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 16 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 2, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 25, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 24, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 21, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 22, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 10, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |